Evidence map›Paper›PMID 25261374›Full record

ArticleOncotarget2014

Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease.

Heidi N Hilton, Tram B Doan, J Dinny Graham, Samantha R Oakes, Audrey Silvestri, Nicole Santucci, Silke Kantimm, Lily I Huschtscha, Christopher J Ormandy, John W Funder and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Differential Effect of 4Current medicinal chemistry · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Heidi N HiltonWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
Tram B DoanWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
J Dinny GrahamWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
Samantha R OakesCancer Research Program and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. St Vincent's Clinical School, St Vincent's Hospital and University of New South Wales, Darlinghurst NSW, Australia.
Audrey SilvestriWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
Nicole SantucciWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
Silke KantimmWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
Lily I HuschtschaChildren's Medical Research Institute, Westmead, New South Wales, Australia.
Christopher J OrmandyCancer Research Program and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. St Vincent's Clinical School, St Vincent's Hospital and University of New South Wales, Darlinghurst NSW, Australia.
John W FunderMIMR-PHI Institute, Clayton, Victoria, Australia.
Evan R SimpsonMIMR-PHI Institute, Clayton, Victoria, Australia.
Elizabeth S KuczekSydney Medical School, University of Sydney, Westmead, NSW, Australia.
Peter J LeedmanLaboratory for Cancer Medicine, Centre for Medical Research, Western Australian Institute for Medical Research and School of Medicine and Pharmacology, the University of Western Australia, Perth, Western Australia, Australia.
Wayne D TilleyDame Roma Mitchell Cancer Research Laboratories, Discipline of Medicine, Hanson Institute, University of Adelaide, Adelaide, South Australia, Australia.
Peter J FullerMIMR-PHI Institute, Clayton, Victoria, Australia.
George E O MuscatInstitute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Christine L ClarkeWestmead Millennium Institute, Sydney Medical School - Westmead, University of Sydney, NSW, Australia.
University of Sydney · AUChildren's Medical Research Institute · AUSt Vincent's Clinic · AUSt Vincent's Hospital · AUUniversity of Adelaide · AUUniversity of Queensland · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cumulative exposure to estrogen (E) and progesterone (P) over the menstrual cycle significantly influences the risk of developing breast cancer. Despite the dogma that PR in the breast merely serves as a marker of an active estrogen receptor (ER), and as an inhibitor of the proliferative actions of E, it is now clear that in the breast P increases proliferation independently of E action. We show here that the progesterone receptor (PR) and ER are expressed in different epithelial populations, and target non-overlapping pathways in the normal human breast. In breast cancer, PR becomes highly correlated with ER, and this convergence is associated with signaling pathways predictive of disease metastasis. These data challenge the established paradigm that ER and PR function co-operatively in normal breast, and have significant implications not only for our understanding of normal breast biology, but also for diagnosis, prognosis and/or treatment options in breast cancer patients.

Indexed as

Signal TransductionAnimalsBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCase-Control StudiesCell LineageCell ProliferationCell Transformation, NeoplasticEpithelial CellsFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimateMammary Glands, AnimalBiomarkers, TumorReceptors, EstrogenReceptors, ProgesteroneRNA, Messenger

Identifiers

PMID25261374
PMCPMC4226711
OpenAlexW1582366755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.